Form 8-K Microbot Medical Inc. For: Dec 08
- Wall Street closes green as GDP data eases recession worries
- Intel sinks after forecasting weaker than expected start to 2023
- Hasbro cuts 15% of workforce, warns for Q4 on weak consumer business
- Visa reports better than expected Q1 results
- Bulls win Tesla 'Super Bowl' on demand as bears focus on plunging gross margins
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Address of Principal Executive Offices) (Zip Code)
telephone number, including area code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On December 8, 2022, Microbot Medical Inc. issued a press release announcing that it continues to strengthen its intellectual property (IP) portfolio, while advancing and securing its global commercialization strategy. It has been granted a third patent in Israel for the LIBERTY® Robotic System, covering the core capabilities of the system, such as a compact robotic device for driving movement of two or more surgical devices and having motors and actuation assemblies encased within the same volume.
The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).
Item 9.01. Financial Statements and Exhibits.
|99.1||Press Release dated December 8, 2022|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|MICROBOT MEDICAL INC.|
|By:||/s/ Harel Gadot|
|Title:||Chief Executive Officer, President and Chairman|
Date: December 8, 2022
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microbot Medical (MBOT) granted U.S. patent for endovascular surgical instrument
- NexPoint Real Estate Finance, Inc. Announces 2022 Dividend Income Tax Treatment
- Peapack-Gladstone Financial Corporation Reports Strong Fourth Quarter Results, as Net Interest Margin Continues to Expand
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!